88 related articles for article (PubMed ID: 3531130)
1. Therapeutic effect of SF-2103A, a novel carbapenem antibiotic, in combination with cefotaxime, cefoperazone and other cephalosporins.
Yoshida T; Kazuno Y; Shomura T; Murata S; Inouye S; Ito T
J Antibiot (Tokyo); 1986 Jul; 39(7):956-65. PubMed ID: 3531130
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of SF-2103A, a novel carbapenem antibiotic, as a beta-lactamase inhibitor.
Niwa T; Yoshida T; Tamura A; Kazuno Y; Inouye S; Ito T; Kojima M
J Antibiot (Tokyo); 1986 Jul; 39(7):943-55. PubMed ID: 3019978
[TBL] [Abstract][Full Text] [Related]
3. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
4. Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors.
Fu KP; Neu HC
J Antimicrob Chemother; 1981 Mar; 7(3):287-92. PubMed ID: 6268598
[No Abstract] [Full Text] [Related]
5. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial.
Li JT; Lu Y; Hou J; Chen YF; Miao JZ; Jia YX; Hou J; Zhang XZ; Chen DK; Hu WZ; Li LJ; Liu DM; Wang Z; Wu J; Gu JM; Wang HL; Zhang YL; Sun L
Clin Infect Dis; 1997 Mar; 24(3):498-505. PubMed ID: 9114206
[TBL] [Abstract][Full Text] [Related]
6. [Antimicrobial activity of sulbactam/cefoperazone. Comparison with other new cephems].
Deguchi K; Yokota N; Koguchi M; Fukayama S; Nishimura Y; Nakane Y; Oda S; Tanaka S; Kato M; Sato K
Jpn J Antibiot; 1987 Oct; 40(10):1752-61. PubMed ID: 3444015
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and antibacterial efficacy in vivo of beta-lactam combinations against Proteus vulgaris.
Dalhoff A; Gehl AE; Gau W; Lode H
Chemotherapy; 1982; 28(6):444-53. PubMed ID: 6761080
[TBL] [Abstract][Full Text] [Related]
8. Experimental efficacy and pharmacokinetic properties of cefpiramide, a new cephalosporin.
Fu KP; Vince T; McCloud S; Gregory FJ; Chiang ST; Hung PP
Drugs Exp Clin Res; 1985; 11(11):787-91. PubMed ID: 3939215
[TBL] [Abstract][Full Text] [Related]
9. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Zhao C; Xie W; Zhang W; Ye Z; Wu H
Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
[TBL] [Abstract][Full Text] [Related]
10. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.
Cherubin CE; Eng RH; Smith SM; Tan EN
J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944
[TBL] [Abstract][Full Text] [Related]
11. [Studies on sulbactam/cefoperazone in the field of pediatrics].
Iwai N; Taneda Y; Shibata M; Mizoguchi F; Katayama M
Jpn J Antibiot; 1984 Oct; 37(10):1859-79. PubMed ID: 6094865
[TBL] [Abstract][Full Text] [Related]
12. [Synergy between sulbactam and ampicillin or cefoperazone in antimicrobial activity against beta-lactamase producing microorganisms. Results with the use of microdilution broth method].
Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukushima Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Sato K
Jpn J Antibiot; 1990 Jul; 43(7):1214-24. PubMed ID: 2232151
[TBL] [Abstract][Full Text] [Related]
13. The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.
Chang PC; Chen CC; Lu YC; Lai CC; Huang HL; Chuang YC; Tang HJ
J Microbiol Immunol Infect; 2018 Apr; 51(2):207-213. PubMed ID: 29037802
[TBL] [Abstract][Full Text] [Related]
14. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
15. Beta-lactamase inhibitory activities and synergistic effects of 5,6-cis-carbapenem antibiotics.
Okonogi K; Harada S; Shinagawa S; Imada A; Kuno M
J Antibiot (Tokyo); 1982 Aug; 35(8):963-71. PubMed ID: 6982889
[TBL] [Abstract][Full Text] [Related]
16. [Clinical studies of sulbactam/cefoperazone therapy in pediatric bacterial infections].
Nakamura A; Himi K; Matsumura C; Suzuki H; Kurosaki T; Sugaya N; Terashima I; Uehara S
Jpn J Antibiot; 1984 Oct; 37(10):1793-800. PubMed ID: 6094859
[TBL] [Abstract][Full Text] [Related]
17. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
[TBL] [Abstract][Full Text] [Related]
18. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Richards DM; Heel RC
Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
[TBL] [Abstract][Full Text] [Related]
19. [Study of in vitro activity of 3 cephalosporins and their combination with 2 beta-lactamase inhibitors against 4 enterobacteria strains producing extended spectrum beta-lactamase].
Cattoen C; Duflos D; Bouillet L; Chatelain C; Mazars E
Pathol Biol (Paris); 1997 May; 45(5):425-9. PubMed ID: 9296097
[TBL] [Abstract][Full Text] [Related]
20. Significance of inducible cephalosporinase remaining in the experimentally infected rat granuloma pouch after beta-lactam therapy.
Araki H; Minami S; Watanabe Y; Yasuda T
Antimicrob Agents Chemother; 1991 Jun; 35(6):1131-6. PubMed ID: 1929254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
